RxDoctor Payments Data

Andrew Smith, MD

Family Medicine · Knoxville, TNNPI 1083660880

Payments from drug & device makers

$11,994in general payments, 2019–2025

Across 672 payments — averaging $17.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • Lilly USA, LLC$2K
  • AstraZeneca$1K
  • Amarin Pharma, Inc.$625
  • Amgen$586
  • plus $5K from 45 others

What the payments were for

  • Consulting fees$4033%
  • Food & beverage$11,54196%
  • Education$500%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,994 in reported general payments places this provider in the 90th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$81,610
Medicare patients
132
Services billed
2,453

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide51$76,778
JardianceEmpagliflozin46$45,539
MounjaroTirzepatide36$45,516
FarxigaDapagliflozin Propanediol34$26,218
EliquisApixaban29$21,681
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$13,761
Bydureon BciseExenatide Microspheres14$11,400
Emgality PenGalcanezumab-Gnlm13$8,935
JanuviaSitagliptin Phosphate16$8,475
Synjardy XrEmpagliflozin/Metformin Hcl12$7,217
Praluent PenAlirocumab11$5,478
Rosuvastatin Calcium334$3,844
Estradiol (Once Weekly)Estradiol11$1,709
Nebivolol Hcl21$1,405
Atorvastatin Calcium111$1,312

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,657$76,77851 claims
Boehringer IngelheimJardiance, Synjardy Xr$277$52,75658 claims
Lilly USA, LLCMounjaro$1,542$45,51636 claims
AstraZenecaFarxiga$1,100$26,21834 claims
PfizerEliquis$353$21,68129 claims
GSKTrelegy Ellipta$207$13,76118 claims
MerckJanuvia$156$8,47516 claims
Sanofi-aventis U.S. LLCLantus$112$68311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →